Loading...
Loading...
Browse all stories on DeepNewz
VisitWhat will be the major political party's stance on the Gabriella Miller Kids First Research Act 2.0 by June 30, 2025?
Supportive • 25%
Opposed • 25%
Neutral • 25%
No official stance • 25%
Statements from party leaders or official party platforms
Senate Passes $190 Million Pediatric Cancer Research Bill, H.R.3391, After House Approval on March 5, 2024, by 384-4 Vote
Dec 20, 2024, 08:40 PM
A $190 million funding bill for pediatric cancer research, known as the Gabriella Miller Kids First Research Act 2.0, was passed by the Republican-controlled House on March 5, 2024, with an overwhelming vote of 384-4. However, the bill has been stalled in the Democrat-controlled Senate, where Senate Majority Leader Chuck Schumer has not brought it up for a vote. This situation has led to accusations against Democrats for allegedly using the funding as a bargaining chip in broader negotiations. Recently, the Senate passed the bill unanimously, allowing it to move to President Biden for final approval. The bill's passage comes after a period of intense political discourse, where Democrats were criticized for blaming Republicans for the funding's delay, despite the bill's prior approval in the House.
View original story
Supportive • 25%
Neutral • 25%
Opposed • 25%
No Statement • 25%
No Action • 25%
Amended • 25%
Passed • 25%
Rejected • 25%
Change Allocation • 25%
Decrease Funding • 25%
No Amendments • 25%
Increase Funding • 25%
Yes • 50%
No • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
Other significant response • 25%
Republicans criticize the bill • 25%
Chuck Schumer praises the bill • 25%
Joe Biden praises the bill • 25%
Significant advancements • 25%
Moderate advancements • 25%
Minimal advancements • 25%
No noticeable advancements • 25%
Bipartisan Effort • 25%
Republican Party • 25%
Other • 25%
Democratic Party • 25%
No • 50%
Yes • 50%
Other • 25%
Bitcoin-related Legislation • 25%
Border Security Measures • 25%
Tax Reform • 25%
No • 50%
Yes • 50%
Yes • 50%
No • 50%
No • 50%
Yes • 50%
Clinical trials • 25%
Other • 25%
Genetic research • 25%
Data infrastructure • 25%